Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear.
Merz Therapeutics has successfully acquired Acorda’s Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) after the latter went bankrupt earlier this year.
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Asahi Kasei's CDMO Bionova is expanding its offerings to include starting materials for innovative medicines such as cell and gene therapies.
US FDA declines to approve Supernus` Parkinson`s combination again
Acorda Therapeutics Announces Nasdaq Delisting Notification
After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal to sell off its assets and a bankruptcy filing.
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
With sales declining for aging multiple sclerosis (MS) drug Fampyra, Biogen has exercised an option to return licensing rights outside of the United States to Acorda Therapeutics.